Physician profile
Kyle E Platz
NPI 1932223690
$51,267.98
in general payments reported to CMS, 2019-2025
56 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $11K · 2021: $14K · 2022: $19K · 2023: $2,118 · 2024: $2,278 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,266 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,266.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43,474.72 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,124.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $827.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $650.24 | 2020-2025 | |
| Pfizer INC. | $612.86 | 2019-2025 | |
| Amgen INC. | $451.72 | 2019-2025 | Prolia, Evenity, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.98 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $334.88 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $308.66 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.44 | 2020-2024 | Xifaxan |
| Watermark Medical, INC. | $207.17 | 2020 | |
| Abbott Laboratories | $191.56 | 2024-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $158.57 | 2020-2021 | |
| Allergan, INC. | $146.87 | 2020 | |
| Upsher-Smith Laboratories LLC | $140.20 | 2020-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Platz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.